

**ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.**

Publicly Held Company – CVM No 2612-3

NIRE 35.300.493.699

CNPJ/MF No 12.104.241/0004-02

**MATERIAL FACT**

**Oncoclínicas do Brasil Serviços Médicos S.A.** (B3: ONCO3) (“Company” or “Oncoclínicas”), in compliance with article 157, paragraph 4, of Law No. 6,404/76 and with CVM Resolution No. 44/21, hereby informs its shareholders and the market in general as follows.

In light of the various ongoing strategic initiatives related to (i) discontinuing non-core operations, and (ii) implementing commercial and operational optimizations, as disclosed by the Company over the past months, Oncoclínicas’ management deems to be appropriate to release the following forecast and projections for Net Revenue, Gross Profit, Gross Margin, EBITDA Ex-LTIP, and EBITDA Ex-LTIP Margin, for the third and fourth quarters of 2025, as well as for the fiscal years of 2026 and 2027.

Additionally – and also due to the aforementioned strategic initiatives (as detailed below), which are aimed at reducing financial leverage and establishing a sustainable cash generation dynamic –, the Company has also chosen to disclose a forecast for the Company’s Net Debt for the end of the third quarter of 2025 and projections for EBITDA to Operational Cash Flow (OCF) Conversion and Capex for the fourth quarter of 2025 as well as for the fiscal years of 2026 and 2027.

The Company notes that (i) the projections were prepared based on the assumptions indicated in this material fact, and (ii) the forecasts for the third quarter of 2025 are preliminary, unaudited, and subject to revision until the date of official disclosure.

<i><b>In millions of Reais (BRL), except otherwise indicated</b></i>	<b>3Q25</b>	<b>4Q25</b>	<b>2026</b>	<b>2027</b>
Net Revenue	1,400	1,470	6,290	6,980
Gross Profit	460	485	2,100	2,340
<i>Gross Margin (%)</i>	32.9%	33.0%	33.4%	33.5%
EBITDA Ex-LTIP	215	235	1,075	1,255
<i>EBITDA Ex-LTIP Margin (%)</i>	15.4%	16.0%	17.1%	18.0%
Net Debt <sup>1</sup>	3,900			
EBITDA to OCF Conversion (%)		50%	55%	60%
Capex		25	80	80

1- Financial Net Debt plus Payables for Acquisitions (Ex-Earn-Outs), as per the concept disclosed by the Company.

## Assumptions for Projections Calculations

Without prejudice to the disclaimers in the “Legal Notice” section below, the projections contained in this Material Fact assume that, starting from fiscal year 2026, the Company will successfully implement the following asset divestments and/or renegotiations of Capex commitments:

- Completion of the sale of Hospital de Oncologia do Méier S.A. (“HMM”) – an initiative addressed by the material fact disclosed by the Company on August 25, 2025;
- Completion of the sale of the 84% interest held by the Company in Complexo Hospitalar Uberlândia S.A. (“UMC”) – an initiative addressed by the material fact disclosed by the Company on August 26, 2025;
- Divestment of the Company’s equity interest in Instituto Materno Infantil de Minas Gerais S.A. (*Hospital Vila da Serra*) (“HVS”);
- Termination or renegotiation, as applicable, of the atypical non-residential real estate lease agreements under “built to suit” modality, executed by the Company, for the construction of three cancer centers (São Paulo, Belo Horizonte, and Goiânia) (“Built to Suit Projects”); and
- Renegotiation of the investment agreement entered into with Advanced Drug Company for Pharmaceuticals for the formation of a joint venture for the development of an oncology treatment operation in Saudi Arabia (“Joint Venture”), such that no further capital contributions will be required from the Company to the Joint Venture.

For clarification, the assumptions consider that, until December 31, 2025, the hospital operations HMM, UMC, and HVS still remain within the Company and, therefore, are reflected in the 3Q25 and 4Q25 figures shown in the above table, therefore negatively impacting them during this period.

Notwithstanding the other disclaimers set forth in the “Legal Notice” section below, Oncoclínicas notes that the projections contained in this Material Fact reflect management’s best estimates based on the effective completion of the initiatives indicated herein. However, there is currently no guarantee that such initiatives will indeed be completed and, consequently, that the above projections will materialize, considering, in particular:

- (i) in the case of the sales of HMM and the Company’s stake in UMC, that the completion of these transactions remains subject to the fulfillment or verification of certain suspensive conditions customary for this type of transaction; and
- (ii) regarding the other initiatives, the need to negotiate and execute definitive agreements with counterparties, whether for (a) entering into a new binding agreement, or (b) terminating and/or



renegotiating existing binding agreements, as well as potential implementation risks of agreed terms.

### **Discontinuation of Saudi Arabia Joint Venture Projection**

The Company has chosen to discontinue the projection regarding Gross Revenue and EBITDA estimates for the Saudi Joint Venture, given the ongoing negotiations to amend the Joint Venture investment agreement.

### **Legal Notice**

*The information contained in this Material Fact consists of mere forecasts, based on current management expectations regarding the future of OncoClínicas. In addition to the disclaimers contained herein, such forecasts are highly dependent on market conditions, Brazil's general economic performance, the industry, and international markets, and do not constitute a performance promise. Therefore, our actual results and performance may differ from those projected in these forward-looking statements. With respect to the preliminary information contained in this Material Fact, the Company notes that such data has not been audited by independent auditors.*

São Paulo, October 1<sup>st</sup>, 2025

**Cristiano Affonso Ferreira de Camargo**  
Chief Financial Officer and Investor Relations Officer  
**ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.**